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Abstract: Gefitinib is the first epidermal growth factor receptor tyrosine-kinase inhibitor
approved for the treatment of advanced non-small cell lung cancer (NSCLC). Its failure to
improve survival in a placebo-control study, however, led to its withdrawal in the United States
though it is available in many other countries Subsequent studies nevertheless showed comparable
efficacy for gefitinib and docetaxel in the second-line therapy. Gefitinib significantly improved
progression-free survival compared to chemotherapy in patients with activating mutations in
the epidermal growth factor receptor tyrosine kinase mutations. This review will discuss the
results of these large randomized studies and discuss the role of gefitinib in the treatment of
advanced NSCLC.
Keywords: gefitinib, non-small cell lung cancer
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Lung cancer is the most common cause of cancer mortality in the United States, with
159,390 deaths estimated for the year 2009 by the American Cancer Society, accounting
for 30% of cancer deaths in men and 26% of cancer deaths in women.1 Approximately
87% of patients have one of the non-small cell lung cancer (NSCLC) histology subtypes.2 The majority of patients present with locally advanced or metastatic disease,3
and relapses are common in those undergoing resection with curative intent, even with
the use of adjuvant chemotherapy.4 Treatment for patients with advanced disease is
largely palliative, and the benefits appear to have reached a plateau with conventional
platinum-based chemotherapy doublets.5 Inhibitors of epidermal growth factor receptor
(EGFR) tyrosine kinase (TK) gefitinib and erlotinib are widely used in the treatment
of advanced NSCLC. This review will focus on the role of gefitinib in the treatment
of patients with advanced NSCLC.
EGFR is a transmembrane glycoprotein, consisting of three main components,
including an extracellular ligand-binding domain, a transmembrane region, and a
tyrosine kinase (TK) region. Binding of one of the ligands to the extracellular domain,
including epidermal growth factor (EGF), transforming growth factor alpha (TGF-α),
beta-cellulin, epiregulin and amphiregulin, leads to receptor dimerization and activation of the TK. The autophosphorylation triggered by the TK promotes multiple
intracellular signaling pathways, ultimately causing cancer cell proliferation, invasion,
and metastases.6 The EGFR pathway may be inhibited by a monoclonal antibody that
prevents the ligand binding or by a small molecule that inhibits the TK activity.
Gefitinib is a low-molecular-weight, synthetic anilinoquinazoline compound that
inhibits autophosphorylation and downstream signaling by reversibly binding to the
Biologics: Targets & Therapy 2010:4 83–90
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ATP site. Initial pharmacokinetic studies in healthy male
volunteers aged 18 to 62 years receiving escalating doses
from 1 mg to 75 mg or 100 mg daily for 3 days, or evaluating the effect of food intake after a single dose of 50 mg,
showed a peak plasma drug concentration (Cmax) between 3
and 7 hours after administration, with a terminal elimination
half-life of 28 hours.7 The Cmax was decreased by 34% with
food ingestion, and the prolonged half-life suggested the
feasibility of once daily administration. Overall, the treatment was well tolerated, with a similar frequency of adverse
effects compared to placebo.

Phase I clinical trials with gefitinib
The early experience with gefitinib in four open-label multicenter phase I trials included patients with a variety of solid
tumors known to have high expression of EGFR, such as
NSCLC, breast, head and neck, colon, and ovarian tumors,
although individual malignancies were not tested for baseline EGFR.8–11 Treatment was overall well tolerated, with
the most common adverse events including rash, diarrhea,
nausea, anorexia, and asthenia. The lowest dose associated
with tumor response was 150 mg daily, and the maximum
tolerated dose was established at 700 mg daily. Given concerns of sub-therapeutic dose administration in some patients
due to pharmacokinetic variability, the lowest dose chosen
for phase II clinical trials was 250 mg daily. The alternative
dose of 500 mg daily was selected as the highest tolerated
dose by most patients. Among the 100 patients with NSCLC
enrolled in the combined 4 studies, 24 achieved stable disease
and 10 had partial response.

Single-agent gefitinib in pretreated
patients
The efficacy of gefitinib in NSCLC was evaluated in two multicenter phase II trials, the Iressa Dose Evaluation in Advanced
Lung Cancer (IDEAL) studies I and II. Both studies were nonplacebo controlled and evaluated gefitinib at doses of 250 mg
or 500 mg daily. The IDEAL-I trial, conducted in 43 centers
worldwide, had approximately 50% of patients from Japan and
enrolled patients who had one or two previous chemotherapy
regimens, including a platinum-based combination.12 There
were no significant differences for the dose of 250 mg compared
to 500 mg, with similar response rates (18.4% versus 19%),
disease control rate (54.4% versus 51.4%), progression-free
survival (PFS) (2.7 months versus 2.8 months), median overall
survival (7.6 months versus 8 months), and 1-year survival
(35% versus 29%). Response rates were significantly better
for Japanese patients compared to non-Japanese (27.5% versus
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10.4%; P = 0.002). The IDEAL-II trial was conducted in 30
US centers and enrolled patients with advanced NSCLC and
progressive disease after two or more regimens, including a
platinum agent and docetaxel.13 Similar to IDEAL-I, there
were no differences between the 250 mg and 500 mg daily
doses according to response rates (12% versus 10%), median
survival (7 months versus 6 months), and projected 1-year
survival (27% versus 24%). Treatment was well tolerated in
both studies, skin rash being the most common side effect.
Since the efficacy was similar between the doses and toxicity
was more frequent in patients receiving 500 mg, the lower dose
became the standard. Clinical predictors for response included
Japanese patients, women, adenocarcinoma histology, never
smokers, and good performance status (0 or 1). Based on these
results, gefitinib received accelerated Food and Drug Administration (FDA) approval on May 5, 2003, as monotherapy for
the treatment of locally advanced or metastatic NSCLC after
progression following treatment with platinum-based therapy
and docetaxel.14
Following accelerated approval in the United States, the
FDA mandated postmarketing trials for this agent to evaluate its efficacy in prolonging survival in comparison to best
supportive care. In the Iressa Survival Evaluation in Lung
Cancer (ISEL) trial,15 a randomized phase III study enrolling patients aged 18 or older, with advanced NSCLC previously treated with 1 or 2 previous regimens and refractory
(progressive disease within 90 days from the last treatment
dose) or intolerant to the last treatment, were randomized to
gefitinib 250 mg daily or placebo in a ratio of 2 to 1. A total
of 1692 eligible patients were accrued from 28 countries
worldwide. The groups were well balanced, 50% received at
least 2 prior chemotherapies, and 90% of the patients were
refractory to the last chemotherapy. After a median followup of 7.2 months, there was no significant benefit for gefitinib
compared to placebo according to median survival (5.6 months
versus 5.1 months) or estimated 1-year survival (27% versus
21%) (hazard ratio [HR] 0.89, 95% confidence interval [CI]
0.77–1.02; P = 0.087). Similarly, despite numerically superior
median survival (6.3 months versus 5.4 months) and 1-year
survival (30% versus 18%), the benefit from gefitinib did not
reach statistical significance compared to best supportive care
in patients with adenocarcinoma (HR 0.84; 95% CI 0.68–1.03;
P = 0.089). Although the primary analysis by log rank test did
not show survival benefit for the gefitinib arm, the preplanned
supportive Cox’s regression analysis, with covariate adjustments
identical to the log rank test, showed a statistically significant
improvement for gefitinib compared to placebo in both overall population (P = 0.03) and adenocarcinoma (P = 0.033).
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Additional pre-planned analyses showed better survival for
gefitinib compared to placebo in non-smokers (8.9 months
versus 6.1 months; P = 0.012) and Asians (9.5 months versus
5.5 months, P = 0.01). On December 17, 2004, AstraZeneca
issued a letter to US physicians reporting the lack of survival
improvement for gefitinib, urging them to consider other treatment options.16 Gefitinib was essentially replaced by erlotinib
after the results of the BR.21 study,17 a randomized phase
III trial showing improved survival for second-line erlotinib
compared to placebo. Although only the erlotinib trial showed
a statistically significant survival improvement over placebo,
there were similar response rates (8% versus 8.9%), stable
disease (32% versus 35%), and 1-year survival (27% versus
31%) for gefitinib and erlotinib, respectively.

Second-line gefitinib compared
to chemotherapy
Four recent studies compared gefitinib 250 mg daily with
docetaxel (60–75 mg/m2 every 3 weeks) in patients with
advanced NSCLC (Table 1). The Second-line Indication
of Gefitinib in NSCLC (SIGN) trial was an international
multicenter trial comparing gefitinib to docetaxel in patients
with advanced NSCLC progressing through one previous
line of chemotherapy.18 Between October 2003 and June
2004, 68 patients were randomized to gefitinib and 73
to docetaxel. Response rates, median PFS, and median
survival for gefitinib and docetaxel were 13.2% and 13.7%,
3 months and 3.4 months, and 7.5 months and 7.1 months,
respectively. Gefitinib was associated with fewer adverse
events overall (51.5% versus 78.9%) and grade 3 or 4 toxicity
(8.8% versus 25.4%). The Iressa as a Second-line Therapy
in Advanced NSCLC (ISTANA) was a multicenter Korean
study that enrolled 82 patients to gefitinib and 79 patients
to docetaxel.19 Response rates for gefitinib were signifi-

cantly higher compared to docetaxel (28.1% versus 7.6%;
P  0.001). Gefitinib was also associated with increased PFS
(P = 0.044), and the overall survival results are still pending.
The V-15-32 study was a multicenter Japanese study enrolling patients with advanced NSCLC previously treated with
one or two lines of chemotherapy.20 Between September
2003 and January 2006, 245 patients were enrolled into the
gefitinib arm and 244 to docetaxel. Response rates were
significantly superior for the gefitinib arm (22.5% versus
12.8% (OR 2.14; 95% CI 1.21–3.78, P = 0.009), median
PFS was identical in both arms (2 months),and median
survival and 1-year survival for gefitinib and docetaxel
were 11.5 months and 47.8% and 14 months and 53.7%,
respectively. Although there were no statistically significant
differences in overall survival (P = 0.33), the predefined criterion for non-inferiority (upper CI limit for HR  1.25) was
not achieved (HR 1.12; 95.24% CI 0.89–1.40). Nevertheless,
despite the lack of proven non-inferiority, the similar survival
and decreased toxicity for gefitinib showed that this agent
remained an effective therapy. The Iressa NSCLC Trial Evaluating Response and Survival versus Taxotere (INTEREST)
was a multicenter randomized phase III trial enrolling patients
with advanced NSCLC who had been previously treated
with a platinum-based chemotherapy.21 In this large study,
733 patients received gefitinib and 733 received docetaxel.
Compared to docetaxel, gefitinib was associated with similar
response rates (9.1% versus 7.6%; OR 1.22, P = 0.33), PFS
(2.2 months versus 2.7 months; HR 1.04, P = 0.47), and
median overall survival (7.6 months versus 8 months; HR
1.020; 95% CI 0.905–1.150). This study, unlike the V-15-32,
met the predefined non-inferiority criterion, which was determined as the upper confidence limit 1.154. Subset analyses
showed longer survival for never smokers, women, Asian
patients, and those with adenocarcinoma, but this survival

Table 1 Recent studies comparing gefitinib 250 mg daily with docetaxel (60–75 mg/m2 every 3 weeks) in patients with advanced NSCLC
Trial (year)

Treatment

Patients

Response (%)

Median PFS (months)

Median OS (months)

SIGN (2005)18

Gefitinib

68

13.2

3

7.5

Docetaxel

73

13.7

3.4

7.1

Gefitinib

82

28.1%

NR

NR

Docetaxel

79

7.6%

NR

NR

Gefitinib

245

22.5

2

11.5

Docetaxelb

244

12.8

2

14

Gefitinib

733

9.1

2.2

7.6

Docetaxela

733

7.6

2.7

8

a

ISTANA (2008)19

a

V-15-32 (2008)20
INTEREST (2008)

21

Docetaxel 75 mg/m
Docetaxel 60 mg/m2
Abbreviations: PFS, progression-free survival; OS, overall survival; NR, not reported.
a

2

b
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prolongation compared to their counterparts was observed in
both the gefitinib and docetaxel arms compared to the rest of
the population. Similar to the other reported trials, toxicity
was significantly lower in the gefitinib arm.
Shepherd and colleagues recently reported the metaanalysis of the four clinical trials comparing gefitinib
with docetaxel. 22 In univariate analysis, gefitinib was
associated with increased response rates (OR 1.65; 95%
CI 1.24–2.21, P = 0.0007) but similar PFS (HR 0.96; 95% CI
0.87–1.05, P = 0.37) and overall survival (HR 1.03; 95% CI
0.93–1.13, P = 0.57). When adjusted for study, smoking history, number of previous chemotherapy regimens, response to
prior therapy, gender, age, and performance status, response
rates remained significantly better for gefitinib (OR 1.58;
95% CI 1.19–2.10, P = 0.001), whereas PFS and overall
survival were similar. Taken together, the current data suggest
that in the second line setting, gefitinib had similar efficacy
as docetaxel but was better tolerated even in molecularly
unselected patients with advanced NSCLC.

Experience with first-line gefitinib
in unselected patients
Multiple trials have evaluated the use of gefitinib in previously
untreated advanced unselected NSCLC patients (Table 2).
Reck and colleagues23 showed a 5% response rate with 40%
stable disease in 58 patients. Median PFS and survival were
7 weeks and 29 weeks, respectively. In contrast, Niho and colleagues24 showed response rate of 30% in 40 eligible patients,
with median survival of 13.9 months and 1-year survival of
55%. Nevertheless, despite encouraging response rates and
survival, 4 patients (10%) developed interstitial lung disease,
which was considered unacceptable, particularly in the firstline setting. The Iressa in NSCLC versus Vinorelbine Investigation in The Elderly (INVITE) was a multicenter randomized

phase II trial comparing gefitinib to vinorelbine 30 mg/m2 on
days 1 and 8 every 21 days in patients aged 70 or older with
chemotherapy-naïve advanced NSCLC.25 The median PFS,
the primary objective of the study, was 2.7 months in patients
treated with gefitinib and 2.9 months in those treated with
vinorelbine (HR 1.19, 95% CI 0.85–1.65, P = 0.31). Median
overall survival for gefitinib and vinorelbine were 5.9 months
and 8 months, respectively (HR 0.98; 95% CI 0.66–1.47).
Treatment was better tolerated in the gefitinib arm. Two large
phase III trials evaluated the role of gefitinib in combination
to chemotherapy compared to chemotherapy alone in previously untreated patients with advanced NSCLC. In both the
Iressa NSCLC Trial Accessing the Combination Treatment
(INTACT)-1 trial,26 in which the control arm included cisplatin
and gemcitabine, and the INTACT-2 trial,27 with carboplatin
and paclitaxel, the addition of gefitinib failed to improve
response rates, PFS, median survival time, or 1-year survival.
In a subset analysis of patients in the INTACT-2 study with
adenocarcinoma and receiving treatment for 90 or more days,
the median survival for patients in the low-dose gefitinib
arm (250 mg day) was significantly higher than placebo
(17.1 months versus 13.6 months, P = 0.05). These findings
suggest that sequential therapy with chemotherapy followed by
gefitinib, rather than concurrent, may be the optimal schedule,
and there could be a role for maintenance gefitinib.
In the phase III West Japan Thoracic Oncology Group
0203, chemotherapy naive patients with advanced NSCLC
were randomized to receive either platinum doublet for up
to 6 cycles or 3 cycles of the same chemotherapy followed
by gefitinib daily until disease progression.28 Although there
was an improvement in the PFS for patients treated with
maintenance gefintinib (4.6 versus 4.2 months, P  0.001),
overall survival, the primary endpoint did not reach statistical significance (13.6 versus 12.8 months, P = 0.10). In the

Table 2 First-line gefitinib in advanced NSCLC
Trial/author (year)

Phase

Treatment

Patients

Response (%)

Median PFS/TTP (months)

Median OS (months)

Reck (2006)23

II

Gefitinib

58

5

1.7

6.7

Niho (2006)

II

Gefitinib

40

30

NA

13.9

III

Gefitinib

97

3.1

2.7

5.9

Vinorelbine

99

5.1

2.9

8

CpGm

324

47.2

6

10.9

CpGmGefitinib 250

336

51.2

5.8

9.9

CpGmGefitinib 500

330

50.3

5.5

9.9

CbPc

345

30

5

9.9

CbPcGefitinib 250

345

30.4

5.3

9.8

CbPcGefitinib 500

347

28.7

4.6

8.7

24

INVITE (2008)25
INTACT-1 (2004)

INTACT-2 (2004)

26

27

III

III

Abbreviations: Cb, carboplatin; Cp, cisplatin; Gm, gemcitabine; Pc, paclitaxel; PFS, progression-free survival; TTP, time to progression; NR, not reported.
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subset of patients with adenocarcinoma however, the gefitinib
use was associated with better overall survival (15.4 versus
14.3 months, P = 0.03).

Patient selection for gefitinib
Since initial trials showed improved responses in never
smokers, patients with EGFR mutation, and bronchioloalveolar histology (BAC), subsequent studies were developed
for these specific patient populations (Table 3).
In the multicenter phase II ONCOBELL study29 enrolling patients who were never smokers or had EGFR positive
by fluorescence in situ hybridization (FISH) and p-AKT
positive irrespective of smoking status, the response rate
and 1-year survival in the 42 available patients were 48%
and 64% respectively.
In the randomized phase III Iressa Pan-Asia Study
(IPASS), previously untreated patients with adenocarcinoma
and history of smoking either less than 100 cigarettes in
their lifetime (non-smokers) or 10 pack-year or less quitting tobacco for at least 15 years (former light smokers)
were randomize to receive first-line gefitinib 250 mg daily
or carboplatin plus paclitaxel.30 Response rates were higher
for the gefitinib arm in both the overall population (43%
versus 33%, P  0.001) and in patients with EGFR mutation (71.2% versus 47.3%, P  0.001%). In contrast, the
response rate was significantly lower for gefitinib compared to
chemotherapy in patients without the EGFR mutation (1.1%
versus 23.5%, P = 0.001). PFS in patients receiving gefitinib
was significantly improved in those with EGFR mutation
(HR for progression 0.48; 95% CI, 0.36–0.64; P  0.001)
but significantly worse in those without the mutation (HR

1.85; 95% CI 2.05–3.98; P  0.001). Significant response
rates and survival were also observed in a Korean study,
where 55% of the 72 patients achieved survival and 76%
were alive at 1 year.31
The two studies evaluating the role of single agent gefitinib in patients with BAC showed response rates of 13%
to 17%, median survival of 13 to 13.3 months, and 1-year
survival rates of 51 to 55%.32,33
In addition to clinical correlates, such as ethnicity, gender,
histology, and smoking status, several molecular features
that are associated with response to EGFR TKIs have been
reported. The first predictor for response discovered was the
activating EGFR mutations in a small region of the EGFR
gene encoding the tyrosine kinase domain.34,35 The most
common of these mutations are an in-frame deletion of
exon 19 and a missense mutation at codon 858 resulting in
arginine–leucine substitution (L858R). Several studies showed
significant improvement in response rates among patients with
activating EGFR gene mutation treated with gefitinib. Small
trials, mostly from Japan and enrolling between 16 and 28
patients with EGFR mutation, showed response rates ranging
from 50% to 90%, and PFS from 7.7 months to 13 months.36–40
In the two studies reporting 1-year survival, it ranged between
79% and 88%. In the larger, predominantly non-Asian,
iTARGET study,41 the response rate and 1-year survival for
patients NSCLC harboring the EGFR mutation and treated
with first-line gefitinib were 55% and 73% respectively.
EGFR gene amplification has also been associated with
response to gefitinib. The EGFR gene is located in the chromosome 7 and may be detected by FISH. Cappuzzo and
colleagues42 showed that true gene amplification by FISH in

Table 3 Single-agent gefitinib in selected patients
Study/author
(year)

Setting

Patients

Response (%)

PFS/TTP
(months)

Median survival
(months)

1-year survival

ONCOBELL (2007)29

Never-smokersa

42

48

6.4

NR

64

Lee (2006)

Never-smokers

55

61

6.5

NR

79

iTARGET (2008)41

EGFR mutation

31

55

9.2

17.5

73

Asahina (2006)36

EGFR mutation

16

75

8.9

NR

88

31

ONCOBELL (2007)

EGFR mutation

42

48

6.4

NR

64

Inoue (2006)37

EGFR mutation

16

75

9.7

NR

NR

Sutani (2006)38

EGFR mutation

27

78

9.4

15.4

NR

Sunaga (2007)39

EGFR mutation

19

84

13

NR

NR

Tamura (2008)40

EGFR mutation

28

75

11.5

NR

79

West (2006)

BAC

101

17

4

13

51

BAC

88

13

2.9

13.3

55

32

Cadranel (2007)33

29

Patients were also enrolled if they had EGFR and p-AKT mutations regardless of smoking status.
Abbreviations: EGFR, epidermal growth factor receptor; PFS, progression-free survival; TTP, time to progression; NR, not reported; BAC, bronchioloalveolar carcinoma.
a
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patients treated with gefitinib (tight EGFR genes clusters and
a ratio of EGFR gene to chromosome 2, or 15 copies of
EGFR per cell in 10 or more of the analyzed cells), or high
polysomy (4 copies in 40% of cells) were associated with
improved response rates (36% versus 3%, P  0.001), time
to progression (9 versus 2.2 months, P  0.001) and median
survival (18.7 versus 10.3 months, P = 0.03) compared to
those without these features. In Oncobell study,29 patients
with EGFR FISH positive status had response rates of 68%
(vs 9.1% in EGFR FISH negative) and TTP of 7.6 months
(vs 2.7 months in EGFR FISH negative). In the retrospective analysis of the ISEL study,15 survival patients treated
with gefitinib was improved compared to placebo in patients
with EGFR amplification by FISH (8.3 versus 4.5 months,
P = 0.067) and decreased in those low EGFR gene copy (4.3
versus 6.2 months, P = 0.417).43 These results contrast to the
In the INTEREST trial,21 where there was no benefit from
the use of gefitinib, compared to docetaxel in patients with
EGFR mutation.
Polymorphisms related to the EGFR pathway have been
studied to predict response to EGFR TKIs. The intron 1 CA
repeat polymorphism has been most studied. Shorter CA
repeats are associated with higher response rates and survival
in patients treated with EGFR TKIs.44,45
K-ras mutations, which are mutually exclusive with
EGFR mutations in lung cancer, are most commonly seen
in smokers and associated with resistance to gefitinib.
Among multiple studies evaluating the use of gefitinib
or erlotinib in patients with K-ras mutations, mutations
were found in approximately 17% of patients by pooled
analysis, with most trials showed no response to TKIs.46
Although K-ras mutations have been strongly associated
with cigarette smoking, a recent study on 482 lung adenocarcinomas showed the presence of K-ras mutations 15%
of never smokers, 22% of former smokers, and 25% of
current smokers.47

Summary
Despite the withdrawal of gefitinib in the United States after
the results from the ISEL study,15 gefitinib continues to be
evaluated in multiple studies and has been shown to have
comparable efficacy to standard chemotherapy in the secondline setting. Gefitinib produces stellar and striking results in
patients with lung cancer whose tumor cells harbor activating
mutations in EGFR TK domain and has now been approved
for use in Europe in this molecularly selected population.
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